Wei Yu

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski et al. · Journal of Thoracic Oncology · 2021 · 283 citations · Full text

Neuro-oncology, Atezolizumab Plus Bevacizumab, Medicine +8

Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials

Julien Mazières, Achim Rittmeyer, Shirish M. Gadgeel et al. · Journal of Thoracic Oncology · 2020 · 192 citations · Full text

Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer

Georg Feldmann, Nils Habbe, S. Dhara et al. · Gut · 2008 · 190 citations · Full text

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · JAMA Oncology · 2023 · 172 citations · Full text

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

David R. Gandara, Joachim von Pawel, Julien Mazières et al. · Journal of Thoracic Oncology · 2018 · 156 citations · Full text

Advanced Nsclc, Oncology, Medicine +4